Michael Barbella, Managing Editor09.27.22
MMS Holdings Inc. has appointed Kelly J. Hill as chief Strategy officer. This appointment reflects the company’s accelerating growth as it continues to deliver data-focused clinical research services.
A long-time member of MMS’ executive leadership team, Hill has more than 20 years of business leadership and has helped the company grow from its inception to a global entity of more than 900 colleagues.
“The new appointment of Kelly to chief Strategy officer and our recent partnership with Lindsay Goldberg puts us in a great position to continue assisting our clients in developing life-changing therapies and bringing them to patients,” said Dr. Uma Sharma, CEO. “Kelly has been a strategic right hand to me at MMS, and with our growth, I look forward to her insights and continued leadership in the years ahead.”
In her new role, Hill leads overall corporate strategy, producing long-term, sustainable success and ensuring the achievement of the company’s goals. In addition, she will champion the company’s partnerships and alliances.
“I’m grateful for the opportunity to oversee our strategy at such an exciting time for our company,” said Hill. “Building on a strong foundation of great people, processes, and exceptional customer service, we will continue to expand our services in support of high-impact clinical research and successful therapy approvals, which is of top importance to every member of our global team.”
MMS Holdings is a data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development enable MMS to create submissions that meet rigorous regulatory standards. The company has a global footprint across four continents.
A long-time member of MMS’ executive leadership team, Hill has more than 20 years of business leadership and has helped the company grow from its inception to a global entity of more than 900 colleagues.
“The new appointment of Kelly to chief Strategy officer and our recent partnership with Lindsay Goldberg puts us in a great position to continue assisting our clients in developing life-changing therapies and bringing them to patients,” said Dr. Uma Sharma, CEO. “Kelly has been a strategic right hand to me at MMS, and with our growth, I look forward to her insights and continued leadership in the years ahead.”
In her new role, Hill leads overall corporate strategy, producing long-term, sustainable success and ensuring the achievement of the company’s goals. In addition, she will champion the company’s partnerships and alliances.
“I’m grateful for the opportunity to oversee our strategy at such an exciting time for our company,” said Hill. “Building on a strong foundation of great people, processes, and exceptional customer service, we will continue to expand our services in support of high-impact clinical research and successful therapy approvals, which is of top importance to every member of our global team.”
MMS Holdings is a data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development enable MMS to create submissions that meet rigorous regulatory standards. The company has a global footprint across four continents.